カテゴリ： GlobalData, アメリカ, 企業調査

Janssen Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Janssen Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013987
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：92
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a healthcare products provider that offers various medicines. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurologics, pain management, women’s health, and among others. It also offers treatments for acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, alzheimer’s disease, epilepsy, migraine prevention and treatment. The company sells its products through a network of distributors across the US. Janssen is headquartered in Titusville, New Jersey, the US.

Janssen Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Venture Financing 19
Alios BioPharma Raises US$41 Million In Series B Venture Financing 19
Partnerships 20
Cerveau Technologies Enters into Agreement with Janssen Pharma 20
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 21
PeptiDream Enters into Agreement with Janssen Pharma 22
Janssen Pharma Enters into Partnership with Premier 23
Renova Therapeutics Enters into Agreement with Janssen Pharma 24
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 25
Janssen Pharma Enters into Partnership with Bird Rock Bio 26
Janssen Pharma and Medicines for Malaria Venture to Develop Injectable Anti-Malarial Agents 27
Karolinska Institutet Partners with Johnson & Johnson Companies 28
DiamiR Enters into Research Agreement with Janssen Pharma 29
Janssen Pharma Enters into Agreement with University of Pennsylvania 30
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 31
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 32
Janssen Pharma Enters into Agreement with University of California, San Diego 33
Cypralis Enters into Research Agreement with Janssen Pharma 34
BlinkBio Enters into Discovery Agreement with Janssen Pharma 35
NeurOp Enters into Research Agreement with Janssen Pharma 36
AC Immune Enters into Research Agreement with Janssen Pharma 37
Alector Enters Into Research Agreement With Janssen Pharma 38
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 39
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 40
Mellitech Enters into Agreement with Janssen Pharma 42
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 43
Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 44
Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 45
Licensing Agreements 46
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 46
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 47
Janssen Pharma Enters into Licensing Agreement with Medivir 48
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 49
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 50
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 51
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 52
Minerva Amends licenses Agreement with Janssen Pharma for MIN-202 53
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 55
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 56
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 57
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 58
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 59
AC Immune Enters into Licensing Agreement with Janssen Pharma 60
Addex Therapeutics Amends Licensing Agreement with Janssen Pharma 61
Janssen Pharma Enters into Licensing Agreement with BiocerOX 62
Orion Enters Into Licensing Agreement With Janssen Pharma 63
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 64
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 65
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 66
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 67
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 68
Shionogi Enters Into Licensing Agreement With Janssen Pharma 70
Depomed Enters Into Licensing Agreement With Janssen Pharma 71
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 72
Alios BioPharma Enters Into Licensing Agreement With Versitech 74
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 75
Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharma 76
Asset Transactions 77
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 77
Vivus Acquires Topiramate Related Patents from Janssen Pharma 79
Acquisition 80
Janssen Pharma Acquires XO1 80
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 81
Valeant Pharma Completes Acquisition Of Ortho Dermatologics From Janssen For US$345 Million 83
Janssen Pharmaceuticals Inc – Key Competitors 84
Janssen Pharmaceuticals Inc – Key Employees 85
Janssen Pharmaceuticals Inc – Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Recent Developments 87
Corporate Communications 87
Sep 13, 2016: J&J submits Ebola vaccine regimen to WHO for EUAL 87
Legal and Regulatory 88
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 88
Government and Public Interest 89
Sep 26, 2017: Janssen Announces HealtheVoices Impact Fund Recipients 89
Product News 90
Jan 12, 2016: Evotec Achieves Important Milestone in TargetAD Collaboration with Janssen in Alzheimer’s Disease 90
Other Significant Developments 91
Oct 09, 2017: Johnson & Johnson investing $350M in EU biologics operation, adding 200 jobs 91
Appendix 92
Methodology 92
About GlobalData 92
Contact Us 92
Disclaimer 92

List of Tables
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Janssen Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Alios BioPharma Raises US$41 Million In Series B Venture Financing 19
Cerveau Technologies Enters into Agreement with Janssen Pharma 20
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 21
PeptiDream Enters into Agreement with Janssen Pharma 22
Janssen Pharma Enters into Partnership with Premier 23
Renova Therapeutics Enters into Agreement with Janssen Pharma 24
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 25
Janssen Pharma Enters into Partnership with Bird Rock Bio 26
Janssen Pharma and Medicines for Malaria Venture to Develop Injectable Anti-Malarial Agents 27
Karolinska Institutet Partners with Johnson & Johnson Companies 28
DiamiR Enters into Research Agreement with Janssen Pharma 29
Janssen Pharma Enters into Agreement with University of Pennsylvania 30
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 31
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 32
Janssen Pharma Enters into Agreement with University of California, San Diego 33
Cypralis Enters into Research Agreement with Janssen Pharma 34
BlinkBio Enters into Discovery Agreement with Janssen Pharma 35
NeurOp Enters into Research Agreement with Janssen Pharma 36
AC Immune Enters into Research Agreement with Janssen Pharma 37
Alector Enters Into Research Agreement With Janssen Pharma 38
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 39
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 40
Mellitech Enters into Agreement with Janssen Pharma 42
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 43
Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 44
Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 45
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 46
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 47
Janssen Pharma Enters into Licensing Agreement with Medivir 48
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 49
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 50
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 51
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 52
Minerva Amends licenses Agreement with Janssen Pharma for MIN-202 53
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 55
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 56
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 57
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 58
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 59
AC Immune Enters into Licensing Agreement with Janssen Pharma 60
Addex Therapeutics Amends Licensing Agreement with Janssen Pharma 61
Janssen Pharma Enters into Licensing Agreement with BiocerOX 62
Orion Enters Into Licensing Agreement With Janssen Pharma 63
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 64
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 65
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 66
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 67
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 68
Shionogi Enters Into Licensing Agreement With Janssen Pharma 70
Depomed Enters Into Licensing Agreement With Janssen Pharma 71
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 72
Alios BioPharma Enters Into Licensing Agreement With Versitech 74
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 75
Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharma 76
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 77
Vivus Acquires Topiramate Related Patents from Janssen Pharma 79
Janssen Pharma Acquires XO1 80
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 81
Valeant Pharma Completes Acquisition Of Ortho Dermatologics From Janssen For US$345 Million 83
Janssen Pharmaceuticals Inc, Key Competitors 84
Janssen Pharmaceuticals Inc, Key Employees 85
Janssen Pharmaceuticals Inc, Other Locations 86
Janssen Pharmaceuticals Inc, Subsidiaries 86

★海外企業調査レポート[Janssen Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Sligro Food Group N.V.：戦略・SWOT・企業財務分析
    Sligro Food Group N.V. - Strategy, SWOT and Corporate Finance Report Summary Sligro Food Group N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Trovagene Inc (TROV)：医療機器：M&Aディール及び事業提携情報
    Summary Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancie …
  • Essel Propack Limited：戦略・SWOT・企業財務分析
    Essel Propack Limited - Strategy, SWOT and Corporate Finance Report Summary Essel Propack Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Chuo Kagaku Co., Ltd.：企業の戦略・SWOT・財務情報
    Chuo Kagaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chuo Kagaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Meiji Seika Pharma Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Meiji Seika Pharma Co Ltd (Meiji Seika Pharma), a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider that carries out manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company provides Streptomycin Meiji, Kanamycin Me …
  • Lagardere SCA：企業の戦略・SWOT・財務情報
    Lagardere SCA - Strategy, SWOT and Corporate Finance Report Summary Lagardere SCA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Black River Electric Cooperative, Inc.：企業の戦略的SWOT分析
    Black River Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • KKR & Co. Inc：企業の戦略・SWOT・財務分析
    KKR & Co. Inc - Strategy, SWOT and Corporate Finance Report Summary KKR & Co. Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • ARK Diagnostics Inc：企業の製品パイプライン分析
    Summary ARK Diagnostics Inc (ARK Diagnostics) is a developer, manufacturer and commercializer of in vitro diagnostic immunoassay products. The company's products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors, gabapentin assay, lam …
  • Chuang’s Consortium International Ltd：企業の戦略・SWOT・財務情報
    Chuang's Consortium International Ltd - Strategy, SWOT and Corporate Finance Report Summary Chuang's Consortium International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Steel Reef Infrastructure Corp：石油・ガス：M&Aディール及び事業提携情報
    Summary Steel Reef Infrastructure Corp (Steel Reef Infrastructure) is a mid-stream company that offers long-term returns through investments in small to midsized infrastructure with focus on the Western Canadian Sedimentary Basin. The company offers services such as construction, operation, manageme …
  • SenGenix Inc：医療機器：M&Aディール及び事業提携情報
    Summary SenGenix Inc (SenGenix) is a medical device company that discovers and develops point-of-care diagnostic tests based on fluorescently responsive sensors for delivering patient data to clinicians. The company develops specific molecular sensors for each analyte in its POCT product portfolio. …
  • Rite Aid Corp (RAD)：製薬・医療：M&Aディール及び事業提携情報
    Summary Rite Aid Corp (Rite Aid) is a retail drugstore chain. The company sells prescription drugs and other merchandise such as over-the-counter (OTC) medications, personal care items, health and beauty aids, cosmetics, household items, beverages, convenience foods, greeting cards, and seasonal mer …
  • Panther Energy Company LLC：石油・ガス：M&Aディール及び事業提携情報
    Summary Panther Energy Company LLC (PEC) is an oil and gas company that offers drilling services. The company’s business activities include exploration, acquisition, development and production of oil, natural gas liquids and natural gas. It carries out grassroots horizontal exploration of unconventi …
  • Royal Dutch Shell plc：企業の戦略・SWOT・財務情報
    Royal Dutch Shell plc - Strategy, SWOT and Corporate Finance Report Summary Royal Dutch Shell plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Foodstuffs South Island Ltd：戦略・SWOT・企業財務分析
    Foodstuffs South Island Ltd - Strategy, SWOT and Corporate Finance Report Summary Foodstuffs South Island Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Maruishi Pharmaceutical Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Maruishi Pharmaceutical Co Ltd (Maruishi) is a pharmaceutical company that develops and sells medical drugs. The company offers products in the fields of perioperative and infection control. Its products include anesthetics, perioperative drugs, pharmacopoeia drugs, and disinfectants and ant …
  • Grasim Industries Ltd (GRASIM)：企業の財務・戦略的SWOT分析
    Grasim Industries Ltd (GRASIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • MediaCorp Pte Ltd：企業の戦略的SWOT分析
    MediaCorp Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Saipem SpA (SPM)-石油・ガス分野：企業M&A・提携分析
    Summary Saipem SpA (Saipem) is an engineering, procurement, construction (EPC) contractor. It provides integrated basic design, Pre-front end engineering design (FEED), FEED and detailed EPC and project management services for complex offshore and onshore projects in the oil and gas industry. The co …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆